The addition of tocilizumab, infliximab, or DNase to patients’ serum in this process led to reduced expression of these molecules, which suggests a role of RA patients’ serum proinflammatory cytokines TNF-α and IL-6 in NET-mediated inflammation and atherothrombotic processes [66,67]. This evidence concerns the gene IL6 and rheumatoid arthritis.